Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > BUSINESS
BUSINESS
- Takao Hayakawa Tapped as New Chief of Kaketsuken
June 22, 2016
- Takeda Kicks Off PIIb Trial for Norovirus Vaccine in US
June 22, 2016
- AnGes MG Alters Global Collategene Strategy, Initial Focus Now on US
June 21, 2016
- Mitsubishi Tanabe Files US NDA for ALS Drug Edaravone, Eyes Nod by March-End
June 21, 2016
- Jannie Oosthuizen to Lead MSD Japan from July
June 21, 2016
- Cyramza Earns Lung Cancer Indication in Japan
June 21, 2016
- Co-Dio AG Makes Debut; Kipres, Ecard AGs to Hit Market Early September
June 20, 2016
- AMED-Backed Neuropathic Pain Drug Now in PI: Nippon Chemiphar, Kyushu University
June 20, 2016
- Takeda Gains Access to US Cancer Genomic Network
June 20, 2016
- Takeda’s Partnership with Tri-I TDI Now Encompasses Antibody Drug Discovery
June 20, 2016
- Novartis Seeks Chronic Hives Indication for Xolair
June 20, 2016
- Aspen Japan Looks to Expand Biz through Essential Drugs, AGs: President
June 20, 2016
- Jardiance Reduces Kidney Disease Risks Too, by 39%
June 17, 2016
- Eisai to Book 9.2 Billion Yen Gain from EA Pharma Share Acquisition
June 17, 2016
- AnGes MG to License Oral CIN Therapeutic Vaccine to Morishita Jintan
June 17, 2016
- PeptiDream’s Macrocyclic Compound Advances to Clinical Stage
June 16, 2016
- Seikagaku Licenses Lumbar Disc Herniation Drug to Ferring
June 16, 2016
- Selexipag Reaches European Soil, Now Available in Germany: Nippon Shinyaku
June 16, 2016
- Novartis Japan to Revamp Ophthalmology Drug Biz amid Global Drive
June 16, 2016
- Roche to Top Global Drug Maker Ranking in 2020, Consulting Firm Predicts
June 16, 2016
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…